Skip to content

Adipose Tissue Gene Expression Profiles in Women With Polycystic Ovary Syndrome (PCOS) Versus Controls

Adipose Tissue Gene Expression Profiles in Women With PCOS Versus Controls Matched for BMI

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01195142
Enrollment
10
Registered
2010-09-06
Start date
2007-12-31
Completion date
2008-07-31
Last updated
2010-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Keywords

PCOS

Brief summary

Adipose tissue is a central organ in mediating metabolic health. There is some evidence that women with polycystic ovary syndrome (PCOS) have a degree of adipose tissue dysfunction which may negatively affect their metabolic health. The aim of this study was to assess transcriptomic profiles of subcutaneous adipose tissue of women with PCOS in comparison with a control population matched on the basis of age and body mass index (BMI). A secondary aim was to then relate these gene expression profiles to the biochemical environment.

Detailed description

Adipose tissue is a central organ in mediating metabolic health. There is some evidence that women with polycystic ovary syndrome (PCOS) have a degree of adipose tissue dysfunction which may negatively affect their metabolic health. The aim of this study was to assess transcriptomic profiles of subcutaneous adipose tissue of women with PCOS in comparison with a control population matched on the basis of age and body mass index (BMI). A secondary aim was to then relate these gene expression profiles to the biochemical environment.

Interventions

None listed

Sponsors

University College Dublin
CollaboratorOTHER
The Adelaide and Meath Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Had a positive diagnosis of PCOS as defined according to the NIH criteria as chronic oligomenorrhoea (\< 9 menstrual cycles per year) and clinical and/or biochemical evidence of hyperandrogenism, in the absence of other disorders causing the same phenotype. Clinical criteria included hirsutism with a Ferriman-Galwey score greater than 9, acne or male pattern alopecia; biochemical criteria included total-testosterone, androstenedione or dehydroepiandrosterone sulphate (DHEAS) greater than the laboratory reference range. * Were between the ages of 18 and 40

Exclusion criteria

* Were under 18 years or greater than 40 years old, * Were non-Caucasian * Were pregnant, lactating or trying to conceive * Had a body mass index (BMI) \<18kg/m2 or \>50kg/m2 * Had a recent illness or any chronic illness likely to influence results * Were taking hormonal contraception

Design outcomes

Primary

MeasureTime frameDescription
Transcriptomic profiling of subcutaneous adipose tissue of women with PCOS and age and BMI matched controlsRecruitment ran from Dec 2007-July 2008. Subjects attended the study location fasting on one occasionGene expression profiles from women with PCOS and controls matched for age and BMI were determined by microarray analysis of whole subcutaneous adipose tissue samples. Single gene changes as well as pathway analyses will be used to determine differently expressed genes and pathways between the PCOS cohort and controls.

Secondary

MeasureTime frameDescription
Measurement of biomarkers of metabolic health (lipid, inflammatory markers) in plasma of PCOS cases and controlsRecruitment ran from Dec 2007-July 2008. Subjects attended the study location fasting on one occasionBiomarkers of metabolic health were assessed in plasma of women with PCOS and age and BMI matched controls. Lipid profile, hormonal profile, various key inflammatory markers and adipokines will be measured. Glucose and insulin concentrations will be assessed also. All parameters will be assessed following a 12 hour over night fast at the study location.

Countries

Ireland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026